Johnson & Johnson Pharmaceutical Research & Development, LLC (CA): In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding

Published: Apr 05, 2011

NEW ORLEANS--(BUSINESS WIRE)--Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized patients with acute medical illnesses.

Back to news